Metagenomi Therapeutics (MGX) Other financing activities (2024 - 2026)
Metagenomi Therapeutics (MGX) posted quarterly Other financing activities of $27000.0 for Q1 2026, down 64.94% year-over-year from $77000.0 in Q1 2025, and down 93.99% quarter-over-quarter from $449000.0 in Q4 2025.
Metagenomi Therapeutics (MGX) Other financing activities (2024 - 2026) Analysis & Trends
Metagenomi Therapeutics (MGX) has reported Other financing activities for 3 consecutive years, with $27000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Other financing activities fell 64.94% year-over-year to $27000.0; the TTM figure through Mar 2026 stood at $508000.0 (up 120.76% YoY), while the FY2025 annual figure was $558000.0, down 99.34% from the prior year.
- Other financing activities fell to $27000.0 in Q1 2026 per MGX's latest filing, from $449000.0 in the prior quarter.
- Across five years, Other financing activities topped out at $86.5 million in Q1 2024 and bottomed at -$2.0 million in Q2 2024.
- Historically, Other financing activities has averaged $10.6 million across 3 years, with a median of $52000.0 in 2025.
- On a YoY basis, Other financing activities climbed as much as 122.15% in 2025 and fell as far as 99.91% in 2025.
- Metagenomi Therapeutics' Other financing activities stood at -$492000.0 in 2024, then jumped by 191.26% to $449000.0 in 2025, then tumbled by 93.99% to $27000.0 in 2026.
- Business Quant data shows MGX's Other financing activities at $27000.0 in Q1 2026, $449000.0 in Q4 2025, and $109000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Metagenomi Therapeutics | 46.51 Mn | 46.51 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 7,000.00 |
| Jun 30, 2026 | 7,000.00 |
| Mar 31, 2026 | 27,000.00 |
| Mar 31, 2026 | 27,000.00 |
| Dec 31, 2025 | 449,000.00 |
| Dec 31, 2025 | 449,000.00 |
| Sep 30, 2025 | 109,000.00 |
| Sep 30, 2025 | 109,000.00 |
| Jun 30, 2025 | -77,000.00 |
| Jun 30, 2025 | -77,000.00 |
| Mar 31, 2025 | 77,000.00 |
| Mar 31, 2025 | 77,000.00 |
| Sep 30, 2024 | -492,000.00 |
| Sep 30, 2024 | -492,000.00 |
| Jun 30, 2024 | -2.03 Mn |
| Jun 30, 2024 | -2.03 Mn |
| Mar 31, 2024 | 86.54 Mn |
| Mar 31, 2024 | 86.54 Mn |